Neville Marks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neville Marks has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Martin J. Berg
4 shared publications- Mariko Saito
Nathan S. Kline Institute for Psychiatric Research
2 shared publications - Martin J. Berg
Nathan S. Kline Institute for Psychiatric Research
2 shared publications Alessandro Guidotti
The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago
1 shared publicationMitsuo Saito
1 shared publication
Latest Publications
- 17 September 2009
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (2) , 181-210
BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis
Secretases are named for enzymes processing amyloid precursor protein (APP), a prototypic type-1 membrane protein. This led directly to discovery of novel Aspartyl proteases (β-secretases or BACE), a tetramer complex γ-secretase (γ-SC) containing presenilins, nicastrin, aph-1 and pen-2, and a new role for metalloprotease(s) of the ADAM family as a α-secretases. Recent advances in defining pathways that mediate endosomal-lysosomal-autophagic-exosomal trafficking now provide targets for new drugs to attenuate abnormal production of fibril forming products characteristic of AD. A key to success includes not only characterization of relevant secretases but mechanisms for sorting and transport of key metabolites to abnormal vesicles or sites for assembly of fibrils. New developments we highlight include an important role for an ‘early recycling endosome’ coated in retromer complex containing lipoprotein receptor LRP-II (SorLA) for switching APP to a non-amyloidogenic pathway for α-secretases processing, or to shuttle APP to a ‘late endosome compartment’ to form Aβ or AICD. LRP11 (SorLA) is of particular importance since it decreases in sporadic AD whose etiology otherwise is unknown.
- 17 September 2009
- Published by Springer Nature in Neurochemical Research
- Vol. 35 (2) , 181-210
BACE and γ-Secretase Characterization and Their Sorting as Therapeutic Targets to Reduce Amyloidogenesis
Secretases are named for enzymes processing amyloid precursor protein (APP), a prototypic type-1 membrane protein. This led directly to discovery of novel Aspartyl proteases (β-secretases or BACE), a tetramer complex γ-secretase (γ-SC) containing presenilins, nicastrin, aph-1 and pen-2, and a new role for metalloprotease(s) of the ADAM family as a α-secretases. Recent advances in defining pathways that mediate endosomal-lysosomal-autophagic-exosomal trafficking now provide targets for new drugs to attenuate abnormal production of fibril forming products characteristic of AD. A key to success includes not only characterization of relevant secretases but mechanisms for sorting and transport of key metabolites to abnormal vesicles or sites for assembly of fibrils. New developments we highlight include an important role for an ‘early recycling endosome’ coated in retromer complex containing lipoprotein receptor LRP-II (SorLA) for switching APP to a non-amyloidogenic pathway for α-secretases processing, or to shuttle APP to a ‘late endosome compartment’ to form Aβ or AICD. LRP11 (SorLA) is of particular importance since it decreases in sporadic AD whose etiology otherwise is unknown.
- 11 July 2007
- Published by Elsevier in Neurochemistry International
- Vol. 52 (1-2) , 184-215
Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders
- 11 July 2007
- Published by Elsevier in Neurochemistry International
- Vol. 52 (1-2) , 184-215
Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders
- 1 July 2003
- Published by Springer Nature in Neurochemical Research
- Vol. 28 (7) , 1049-1062
APP Processing Enzymes (Secretases) as Therapeutic Targets: Insights from the Use of Transgenics (Tgs) and Transfected Cells
Secretases degrade amyloid precursor protein (APP) releasing fragments (β-peptides Aβ, Aβx) that assemble to form hallmark extracellular deposits in Alzheimer's disease (AD) correlating with disease...
- 1 July 2003
- Published by Springer Nature in Neurochemical Research
- Vol. 28 (7) , 1049-1062
APP Processing Enzymes (Secretases) as Therapeutic Targets: Insights from the Use of Transgenics (Tgs) and Transfected Cells
Secretases degrade amyloid precursor protein (APP) releasing fragments (β-peptides Aβ, Aβx) that assemble to form hallmark extracellular deposits in Alzheimer's disease (AD) correlating with disease...
- Open Access
- 1 September 1999
- Published by Elsevier in Neurochemistry International
- Vol. 35 (3) , 195-220
Recent advances on neuronal caspases in development and neurodegeneration
- 1 September 1999
- Published by Elsevier in Neurochemistry International
- Vol. 35 (3) , 195-220
Open AccessRecent advances on neuronal caspases in development and neurodegeneration
- 1 May 1998
- Published by Wiley in Journal of Neuroscience Research
- Vol. 52 (3) , 334-341
Activation of caspase-3 and apoptosis in cerebellar granule cells
Caspase-3 activity increased dramatically in cytosolic extracts of rat cerebellar granule cells exposed to apoptotic conditions (basal medium Eagle (BME) containing 5 mM K+ without serum) when assayed with Ac-DEVD-amc,but not with Ac-YVAD-afc, a preferred substrate for caspase-1. This provided a basis to examine relationships between enzyme activity and cell viability for purposes of selecting an optimal time for comparing neuroprotective agents or strategies. Exposure of neurons to an apoptotic medium containing 5 mM K+ in absence of serum led to a rapid 5- to 10-fold increase in caspase-3 within 2-4 hr but without significant cell loss, or morphological alterations. Exposure to apoptotic medium followed by replacement with maintenance medium containing 25 mM K+and serum led to a rapid fall in caspase-3 and prevention of cell death. This strategy was not effective after 13 hr exposure despite a large fall in enzyme activity. These temporal changes infer systems for rapid enzyme turnover and/or activation of cytoplasmic components linked to later DNA degradation. The effects of cycloheximide point to requirements for protein synthesis, and those of Glu exclude a caspase-3 dependent pathway for necrotic cell damage. Brief treatment with 10 μM LIGA20, an anti-necrotic agent, also attenuated cell loss and caspase-3 activity, indicating a broad spectrum of neuroprotection. Rapid and long-lasting effects, together with its biophysical properties, suggest that this semisynthetic ganglioside acted upstream at or near a membrane site. As such, gangliosides provide useful agents to further probe pathways relevant to neuronal death in culture. J. Neurosci. Res. 52:334–341, 1998.
- 1 May 1998
- Published by Wiley in Journal of Neuroscience Research
- Vol. 52 (3) , 334-341
Activation of caspase-3 and apoptosis in cerebellar granule cells
Caspase-3 activity increased dramatically in cytosolic extracts of rat cerebellar granule cells exposed to apoptotic conditions (basal medium Eagle (BME) containing 5 mM K+ without serum) when assayed with Ac-DEVD-amc,but not with Ac-YVAD-afc, a preferred substrate for caspase-1. This provided a basis to examine relationships between enzyme activity and cell viability for purposes of selecting an optimal time for comparing neuroprotective agents or strategies. Exposure of neurons to an apoptotic medium containing 5 mM K+ in absence of serum led to a rapid 5- to 10-fold increase in caspase-3 within 2-4 hr but without significant cell loss, or morphological alterations. Exposure to apoptotic medium followed by replacement with maintenance medium containing 25 mM K+and serum led to a rapid fall in caspase-3 and prevention of cell death. This strategy was not effective after 13 hr exposure despite a large fall in enzyme activity. These temporal changes infer systems for rapid enzyme turnover and/or activation of cytoplasmic components linked to later DNA degradation. The effects of cycloheximide point to requirements for protein synthesis, and those of Glu exclude a caspase-3 dependent pathway for necrotic cell damage. Brief treatment with 10 μM LIGA20, an anti-necrotic agent, also attenuated cell loss and caspase-3 activity, indicating a broad spectrum of neuroprotection. Rapid and long-lasting effects, together with its biophysical properties, suggest that this semisynthetic ganglioside acted upstream at or near a membrane site. As such, gangliosides provide useful agents to further probe pathways relevant to neuronal death in culture. J. Neurosci. Res. 52:334–341, 1998.